ATE324448T1 - Design von immunogene - Google Patents

Design von immunogene

Info

Publication number
ATE324448T1
ATE324448T1 AT00964541T AT00964541T ATE324448T1 AT E324448 T1 ATE324448 T1 AT E324448T1 AT 00964541 T AT00964541 T AT 00964541T AT 00964541 T AT00964541 T AT 00964541T AT E324448 T1 ATE324448 T1 AT E324448T1
Authority
AT
Austria
Prior art keywords
response
immunogen
virus
type
immunogene
Prior art date
Application number
AT00964541T
Other languages
English (en)
Inventor
Christopher Jones
Andrew Bacon
Gill Douce
Mark Page
Original Assignee
Celltech Pharma Europ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9923902.2A external-priority patent/GB9923902D0/en
Priority claimed from GB0007789A external-priority patent/GB0007789D0/en
Application filed by Celltech Pharma Europ Ltd filed Critical Celltech Pharma Europ Ltd
Application granted granted Critical
Publication of ATE324448T1 publication Critical patent/ATE324448T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Manufacture Of Tobacco Products (AREA)
AT00964541T 1999-10-08 2000-10-06 Design von immunogene ATE324448T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923902.2A GB9923902D0 (en) 1999-10-08 1999-10-08 T-helper cell responses to proteins
GB0007789A GB0007789D0 (en) 2000-03-30 2000-03-30 Designing immunogens

Publications (1)

Publication Number Publication Date
ATE324448T1 true ATE324448T1 (de) 2006-05-15

Family

ID=26243998

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964541T ATE324448T1 (de) 1999-10-08 2000-10-06 Design von immunogene

Country Status (7)

Country Link
US (1) US20040106174A1 (de)
EP (1) EP1218514B1 (de)
JP (1) JP2003511075A (de)
AT (1) ATE324448T1 (de)
AU (1) AU7546500A (de)
DE (1) DE60027581T2 (de)
WO (1) WO2001027281A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02009895A (es) * 2000-04-07 2004-09-06 Univ Leeds Innovations Ltd Proteinas de fusion de antigeno de nucleo de hepatitis b.
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
KR101944263B1 (ko) * 2012-06-11 2019-02-01 시아먼 유니버시티 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체
CN114729010A (zh) * 2019-08-29 2022-07-08 维尔生物科技有限公司 乙型肝炎病毒疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158769A (en) * 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
AU4659993A (en) * 1992-07-07 1994-01-31 Merck & Co., Inc. Vaccine comprising mixed pres1+pres2+s and core particle
MXPA02009895A (es) * 2000-04-07 2004-09-06 Univ Leeds Innovations Ltd Proteinas de fusion de antigeno de nucleo de hepatitis b.
CA2413546C (en) * 2000-06-22 2011-06-14 Celltech Pharmaceuticals Limited Modification of hepatitis b core antigen
US6896944B2 (en) * 2001-06-29 2005-05-24 3M Innovative Properties Company Imaged articles comprising a substrate having a primed surface
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US20030198645A1 (en) * 2002-02-21 2003-10-23 Mark Page Stabilized HBc chimer particles as therapeutic vaccine for chronic hepatitis

Also Published As

Publication number Publication date
DE60027581T2 (de) 2007-05-10
EP1218514A1 (de) 2002-07-03
WO2001027281A1 (en) 2001-04-19
AU7546500A (en) 2001-04-23
EP1218514B1 (de) 2006-04-26
DE60027581D1 (de) 2006-06-01
JP2003511075A (ja) 2003-03-25
US20040106174A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
ATE517909T1 (de) Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
NO20063026L (no) Antistoffer
DE69406423D1 (de) Methode zum überbringen von agenzien an zielzellen
ATE490969T1 (de) Modifizierte transferrin-fusionsproteine
HUP0303753A2 (hu) Fúziós fehérjék immunogenitásának csökkentése
ATE500323T1 (de) Subtilisin-variante
BRPI0516356A (pt) terapia à base de levedura para infecções crÈnicas da hepatite c
DK1328547T3 (da) Identifikation og modifikation af immundominante epitoper i polypeptider
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
BR0309963A (pt) Proteìna de fusão das proteìnas reguladoras/acessórias do hiv
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
ATE324448T1 (de) Design von immunogene
ES2145742T3 (es) Uso de una proteasa de herpes.
DK1501936T3 (da) Familie af cytokin-proteiner
SE9903031D0 (sv) Peptide mixture and vaccine against a chronic viral infection
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
Mayor et al. Functional and immunological characterization of a Duffy binding-like alpha domain from Plasmodium falciparum erythrocyte membrane protein 1 that mediates rosetting
DE60036555D1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
DK1374895T3 (da) Farmaceutisk sammensætning af F(AB) 2-fragmenter af antistoffer og fremgangsmåde til fremstilling heraf
WO2003097814A3 (en) Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
HUP0200302A2 (en) Malaria vaccine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties